Phase I study of cabazitaxel (Cbz) plus cisplatin (Cis) in patients (pts) with advanced solid tumors: Substudy to evaluate the impact of a strong CYP3A inhibitor (ketoconazole; K) or inducer (rifampicin; R) on the pharmacokinetics (PK) of Cbz.
Alain C. Mita
No relevant relationships to disclose
Albert C. Lockhart
Research Funding - Amgen; Bayer; Genentech; Lilly; Merck; Millennium; Novartis; Pfizer
James Lloyd Wade
No relevant relationships to disclose
John Charles Morris
No relevant relationships to disclose
Olivier Rixe
Research Funding - Sanofi
Jean-François Dedieu
Employment or Leadership Position - Sanofi
Stock Ownership - Sanofi
Claudine Wack
Employment or Leadership Position - Sanofi
Laurent Kassalow
Consultant or Advisory Role - Sanofi
John Sarantopoulos
No relevant relationships to disclose